Baird served as a co-manager on this offering.
AboutNanoString Technologies, Inc. (“NanoString” or the “Company”) (NASDAQ: NSTG) recently completed a follow-on offering of 3,318,917 shares of common stock at a price of $18.50 per share, generating gross proceeds of $61.4 million. The Company intends to use the net proceeds from the offering to further commercialize Prosigna™ Breast Cancer Prognostic Gene Signature Assay, including establishing a dedicated oncology sales force, to expand the clinical utility of Prosigna and develop other potential diagnostic product opportunities, to expand life sciences commercial operations to grow and support the installed base of the nCounter Analysis Systems among life sciences research customers in the United States and internationally, to develop new life sciences applications, chemistry and instrumentation for the nCounter technology platform and for working capital and other general corporate purposes.
NanoString provides life science tools for translational research and molecular diagnostic products. The Company's nCounter® Analysis System, which has been employed in basic and translational research since it was first introduced in 2008, has also now been applied to diagnostic use as the nCounter Dx Analysis System. The Company's technology offers a cost-effective way to profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. The Company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic assay to be marketed through the Company's diagnostics business. NanoString is headquartered in Seattle, Washington.
For additional information about this transaction, please contact:
- January 2014
- NanoString Technologies, Inc.
- Target Location
- North America